Literature DB >> 28089157

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

Justin M Allen1, Alexa B Schrock2, Rachel L Erlich2, Vincent A Miller2, Philip J Stephens2, Jeffrey S Ross2, Sai-Hong Ignatius Ou3, Siraj M Ali2, Davood Vafai4.   

Abstract

Entities:  

Keywords:  Acquired resistance; EGFR mutation; FGFR3 fusion; Non–small-cell lung cancer; ctDNA

Mesh：

Substances：

Year:  2016        PMID： 28089157     DOI： 10.1016/j.cllc.2016.12.006

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  6 in total

1.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

Authors:  Caroline E McCoach; Collin M Blakely; Kimberly C Banks; Benjamin Levy; Ben M Chue; Victoria M Raymond; Anh T Le; Christine E Lee; Joseph Diaz; Saiama N Waqar; William T Purcell; Dara L Aisner; Kurtis D Davies; Richard B Lanman; Alice T Shaw; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

2.  BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.

Authors:  Yuri Sheikine; Dean Pavlick; Samuel J Klempner; Sally E Trabucco; Jon H Chung; Mark Rosenzweig; Kai Wang; Vamsidhar Velcheti; Garrett M Frampton; Nir Peled; Molly Murray; Young Kwang Chae; Lee A Albacker; Laurie Gay; Hatim Husain; James H Suh; Sherri Z Millis; Venkataprasanth P Reddy; Julia A Elvin; Ryan J Hartmaier; Afshin Dowlati; Phil Stephens; Jeffrey S Ross; Trever G Bivona; Vincent A Miller; Shridar Ganesan; Alexa B Schrock; Sai-Hong Ignatius Ou; Siraj M Ali
Journal:  JCO Precis Oncol       Date:  2018-04-19

Review 3.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

4.  FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).

Authors:  Ari Raphael; Elizabeth Dudnik; Dov Hershkovitz; Suyog Jain; Steve Olsen; Lior Soussan-Gutman; Taly Ben-Shitrit; Addie Dvir; Hovav Nechushtan; Nir Peled; Amir Onn; Abed Agbarya
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

5.  A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT.

Authors:  David S Tsao; Sukrit Silas; Brian P Landry; Nelda P Itzep; Amy B Nguyen; Samuel Greenberg; Celeste K Kanne; Vivien A Sheehan; Rani Sharma; Rahul Shukla; Prem N Arora; Oguzhan Atay
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

6.  Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.

Authors:  Vincent Plagnol; Samuel Woodhouse; Karen Howarth; Stefanie Lensing; Matt Smith; Michael Epstein; Mikidache Madi; Sarah Smalley; Catherine Leroy; Jonathan Hinton; Frank de Kievit; Esther Musgrave-Brown; Colin Herd; Katherine Baker-Neblett; Will Brennan; Peter Dimitrov; Nathan Campbell; Clive Morris; Nitzan Rosenfeld; James Clark; Davina Gale; Jamie Platt; John Calaway; Greg Jones; Tim Forshew
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.